FDA Warns Consumers About the Dangers of Viekira Pak

The United States Food and Drug Administration (FDA) released a safety warning in 2016 warning consumers that the use of Viekira Pak, a hepatitis C medication, can cause serious liver damage, acute liver failure, liver transplant, multi-organ failure and death, particularly in patients with existing liver conditions.

Viekira Pak is a fixed-dose combination of ritonavir, paritaprevir, ombitasvir, and dasabuvir that can be used along with another hepatitis C medicine, ribavirin. Viekira Pak is an FDA approved antiviral drug marketed by AbbVie. Physicians prescribe the drug to treat chronic Hepatitis C infection including those with compensated cirrhosis.

Patients using these medications have been advised to contact a medical professional as soon as possible if they develop signs of worsening liver disease or injury. Symptoms include:

  • Edema
  • Abdominal swelling
  • Nausea/vomiting
  • Yellowing of the skin and eyes
  • Mental confusion
  • Sleepiness
  • Upper right abdomen pain
  • Decreased urinary output
  • Fatigue
  • Tremors

These side effects can occur within 1-4 weeks of treatment after the use of Viekira Pak.

Fleming, Nolen & Jez is a Houston, Texas-based law firm actively investigating drug-induced liver injuries and deaths related to Viekira Pak. If you suffered serious complications caused by the use of this drug, contact us today to discuss your potential legal options by calling us at (866) 977-6671 or by requesting a free consultation through our online form.

Related Posts: